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See related Letter by Lewis and Caplan, http://ccforum.biomedcentral.com/articles/10.1186/s13054-016-1561-5
The author is grateful for the opportunity to write
this rebuttal to Dr. Ariane Lewis and Dr. Arthur
Caplan’s “Response to a Trial on Reversal of Death by
Neurologic Criteria”.
While the time Dr. Lewis and Dr. Caplan took to write is
appreciated, their critique ignores key learnings from both
recent biomedical history and parallel research disciplines
within the life sciences, and shows intransigence in an era
of novel clinical development models, emerging legislative
initiatives regarding no-option patients, and regulatory ad-
vantages brought about by the globalization of health care.
Living cadaver research has been pursued legally and
ethically in many countries, including the USA (http://arti-
cles.baltimoresun.com/2003-02-02/news/0302020371_1_re-
search-living-dead-university-of-pittsburgh), for years now,
to utilize the human model in toxicology, pharmacokinetic,
and pharmacodynamic studies, as well as for the testing of
novel surgical techniques and medical devices.
Since the early days of regenerative biology, it has been
well known that a range of nonhuman organisms can re-
pair, regenerate, and remodel substantial portions of their
brain and brain stem even after critical life-threatening
trauma, including certain amphibians (http://onlinelibrary.
wiley.com/doi/10.1111/j.1440-169X.2007.00914.x/pdf), fish,
planarians, metamorphic insects, and small hibernating
mammals.
There have been dozens of reported cases (http://
www.ncbi.nlm.nih.gov/pubmed/19818943) in the lit-
erature violating the irreversibility label of the 1968
Harvard ad-hoc brain death criteria, primarily in
young subjects who most likely retain some neuro-
genic niche. Although controversial and resulting in
poor outcomes, such cases highlight that things are
not always black or white in our understanding of the
severe disorders of consciousness.
Epimorphosis is a highly complex form of regeneration
involving many synergistic mechanisms (http://onlineli-
brary.wiley.com/doi/10.1002/dvdy.22553/pdf), including
but not limited to cellular reprogramming, targeted hist-
olysis, and modulation of the innate immune response.
In spite of the comfort that the flawed, reductionist drug
development model brings to the evidence-based medi-
cine dynamic, any “single magic bullet” approach to re-
capitulate such dynamics would be fairly futile, and
instead requires creative thinking, especially in an era of
personalization of medicine, adaptive clinical trial design,
and ongoing legislative initiatives for experimental ther-
apy access for “living” patients.
“False hope” is unfortunately created by a global med-
ical establishment that the public sees generating $7 tril-
lion annually, yet provides no cures for most of the
chronic degenerative diseases responsible for human suf-
fering and death. Exploratory research programs of this
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